• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Goldilocks Time for Remdesivir - Is Any Indication Just Right?

作者信息

Heil Emily L, Kottilil Shyam

机构信息

From the Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy (E.L.H.), and the Institute of Human Virology, University of Maryland School of Medicine (S.K.), Baltimore.

出版信息

N Engl J Med. 2022 Jan 27;386(4):385-387. doi: 10.1056/NEJMe2118579. Epub 2021 Dec 22.

DOI:10.1056/NEJMe2118579
PMID:34936760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8757566/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487e/8757566/ee7e5ffd9683/NEJMe2118579_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487e/8757566/ee7e5ffd9683/NEJMe2118579_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487e/8757566/ee7e5ffd9683/NEJMe2118579_f1.jpg

相似文献

1
The Goldilocks Time for Remdesivir - Is Any Indication Just Right?瑞德西韦的“刚好合适”时机——有合适的迹象吗？
N Engl J Med. 2022 Jan 27;386(4):385-387. doi: 10.1056/NEJMe2118579. Epub 2021 Dec 22.
2
Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy.瑞德西韦和GS-441524在持续低效血液透析（PIRRT）和Seraph 100治疗期间的药代动力学
Clin J Am Soc Nephrol. 2021 Aug;16(8):1256-1257. doi: 10.2215/CJN.17601120. Epub 2021 Jul 23.
3
Emergency Use Authorization for Remdesivir and Its Potential Implications.瑞德西韦的紧急使用授权及其潜在影响。
Ther Innov Regul Sci. 2021 Mar;55(2):270-271. doi: 10.1007/s43441-020-00212-5. Epub 2020 Sep 3.
4
FDA Approval of Remdesivir - A Step in the Right Direction.美国食品药品监督管理局对瑞德西韦的批准——朝着正确方向迈出的一步。
N Engl J Med. 2020 Dec 31;383(27):2598-2600. doi: 10.1056/NEJMp2032369. Epub 2020 Dec 2.
5
Assessing the evidence on remdesivir.评估关于瑞德西韦的证据。
Lancet Infect Dis. 2021 Dec;21(12):1630-1631. doi: 10.1016/S1473-3099(21)00695-2.
6
A Potential Antiviral Treatment for COVID-19: Remdesivir.一种针对新冠病毒病的潜在抗病毒疗法：瑞德西韦。
Clin Nurse Spec. 2020 Nov/Dec;34(6):257-260. doi: 10.1097/NUR.0000000000000549.
7
Remdesivir: a pendulum in a pandemic.瑞德西韦：大流行中的钟摆。
BMJ. 2020 Nov 24;371:m4560. doi: 10.1136/bmj.m4560.
8
Remdesivir: A giant step, or a tiptoe?瑞德西韦：是一大步，还是一小步？
Clin Dermatol. 2020 Nov-Dec;38(6):773-774. doi: 10.1016/j.clindermatol.2020.05.015. Epub 2020 May 13.
9
Early remdesivir treatment in COVID-19: Why wait another day?新冠疫情中早期使用瑞德西韦治疗：为何还要再等一天？
J Med Virol. 2021 Jul;93(7):4078-4080. doi: 10.1002/jmv.26792. Epub 2021 Feb 1.
10
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.

引用本文的文献

1
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.用于冠状病毒感染的抗病毒疗法的靶向内溶酶体纳米颗粒递送
Life Sci Alliance. 2025 Feb 3;8(4). doi: 10.26508/lsa.202403182. Print 2025 Apr.
2
Factors Associated with Prolonged SARS-CoV-2 Viral Positivity in an Italian Cohort of Hospitalized Patients.意大利住院患者队列中与新冠病毒长期阳性相关的因素
Diseases. 2024 Jun 28;12(7):138. doi: 10.3390/diseases12070138.
3
Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency.

本文引用的文献

1
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
2
Heavily mutated Omicron variant puts scientists on alert.高度变异的奥密克戎毒株使科学家们警觉起来。
Nature. 2021 Dec;600(7887):21. doi: 10.1038/d41586-021-03552-w.
3
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
瑞德西韦治疗 COVID-19 住院患者的有效性和安全性：医疗紧急情况下单中心观察研究真实世界数据的倾向评分分析。
Clin Drug Investig. 2023 Oct;43(10):763-771. doi: 10.1007/s40261-023-01304-4. Epub 2023 Sep 22.
4
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia.用于治疗新冠病毒肺炎的Janus激酶抑制剂综述
Inflamm Regen. 2023 Jan 9;43(1):3. doi: 10.1186/s41232-022-00253-3.
5
Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease.谷胱甘肽缺乏在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染发病机制中的作用及其对重症2019冠状病毒病（COVID-19）宿主免疫反应的影响
Front Microbiol. 2022 Oct 6;13:979719. doi: 10.3389/fmicb.2022.979719. eCollection 2022.
6
Persistent RNA SARS-CoV-2 Detection in a HIV-Infected Patient.一名HIV感染患者体内持续检测到新冠病毒RNA
Healthcare (Basel). 2022 May 25;10(6):982. doi: 10.3390/healthcare10060982.
7
Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy.早期瑞德西韦预防意大利北部实体器官移植受者发生严重 COVID-19：一项真实世界研究。
Int J Infect Dis. 2022 Aug;121:157-160. doi: 10.1016/j.ijid.2022.05.001. Epub 2022 May 6.
8
[Not Available].
Pneumo News. 2022;14(2):14. doi: 10.1007/s15033-022-2814-4. Epub 2022 May 3.
9
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.瑞德西韦和其他三种药物治疗 COVID-19 住院患者：世卫组织团结随机试验的最终结果和更新的荟萃分析。
Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2.
10
Response: Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.回应：评论：模式识别蛋白：对抗冠状病毒的第一道防线。
Front Immunol. 2022 Apr 12;13:853015. doi: 10.3389/fimmu.2022.853015. eCollection 2022.
瑞德西韦联合标准治疗与单纯标准治疗用于治疗因 COVID-19 住院的患者（DisCoVeRy）：一项 3 期、随机、对照、开放标签试验。
Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.
4
Uptake of Outpatient Monoclonal Antibody Treatments for COVID-19 in the United States: a Cross-Sectional Analysis.美国门诊使用单克隆抗体治疗新冠病毒病的情况：一项横断面分析
J Gen Intern Med. 2021 Dec;36(12):3922-3924. doi: 10.1007/s11606-021-07109-5. Epub 2021 Sep 8.
5
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响：一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
6
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
7
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
8
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
9
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.